Literature DB >> 6090311

The inactivation of the polymorphonuclear leukocyte by non-steroidal anti-inflammatory drugs.

S Abramson, H Edelson, H Kaplan, W Given, G Weissmann.   

Abstract

When human neutrophils (PMNs) are activated by appropriate stimuli, they aggregate, generate superoxide anion (O2-) and secrete lysosomal enzymes. Pre-incubation of PMNs in vitro with the cyclo-oxygenase (COx) inhibitor piroxicam (50 microM) before stimulation with the chemotactic peptide f-met-leu-phe (FMLP, 10(-7)M) inhibited all of these responses. The COx inhibitor ibuprofen inhibited FMLP-induced aggregation and lysozyme secretion, leaving O2- generation unaffected. Binding of 3H-FMLP was inhibited by piroxicam. When the plant lectin concanavalin A (Con-A, 30 micrograms/ml) or the tumor promoter phorbol myristate acetate (PMA, 50 micrograms/ml) was used as a stimulus, ibuprofen had no effect on PMN response, while piroxicam inhibited only O2- generation. To determine whether such inhibition might also occur in vivo, we tested neutrophil aggregation and O2- generation in response to FMLP in 26 normal subjects. These subjects were then administered therapeutic doses of piroxicam (20 mg/day), ibuprofen (2400 mg/day) or indomethacin (100 mg/day), and neutrophil functions were retested after 3 days. Piroxicam inhibited FMLP-induced aggregation by 31% (5.2 cm2/min versus 3.6 cm2/min, P less than 0.004) and O2- generation by 35% (15.8 nmol cytochrome c reduced versus 10.2 nmol, P less than 0.002). Ibuprofen inhibited FMLP-induced aggregation by 44% (5.2 versus 3.0, P less than 0.03) but had no effect on O2- production. Indomethacin inhibited FMLP-induced aggregation (6.4 versus 2.9, P less than 0.01) but had no effect on O2- generation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6090311     DOI: 10.1007/bf00915717

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  9 in total

1.  The generation of O2-by the interaction of the hemolytic agent, phenylhydrazine, with human hemoglobin.

Authors:  B Goldberg; A Stern
Journal:  J Biol Chem       Date:  1975-03-25       Impact factor: 5.157

Review 2.  Collagenolytic systems in rheumatoid arthritis.

Authors:  E D Harris; C S Faulkner; F E Brown
Journal:  Clin Orthop Relat Res       Date:  1975 Jul-Aug       Impact factor: 4.176

3.  Breakdown of cartilage proteinpolysaccharide by lysosomes.

Authors:  G Weissmann; I Spilberg
Journal:  Arthritis Rheum       Date:  1968-04

4.  In vivo synthesis of IgG by rheumatoid synovium.

Authors:  A J Sliwinski; N J Zvaifler
Journal:  J Lab Clin Med       Date:  1970-08

5.  Arthritis induced in rabbits by lysates of granulocyte lysosomes.

Authors:  G Weissmann; I Spilberg; K Krakauer
Journal:  Arthritis Rheum       Date:  1969-04

6.  Metabolic changes in rabbit articular cartilage due to inflammation.

Authors:  K Deshmukh; S Hemrick
Journal:  Arthritis Rheum       Date:  1976 Mar-Apr

7.  The roles of degranulation and superoxide anion generation in neutrophil aggregation.

Authors:  H B Kaplan; H S Edelson; R Friedman; G Weissmann
Journal:  Biochim Biophys Acta       Date:  1982-09-13

Review 8.  Granulocyte elastase at the site of cartilage erosion by rheumatoid synovial tissue.

Authors:  H Menninger; R Putzier; W Mohr; D Wessinghage; K Tillmann
Journal:  Z Rheumatol       Date:  1980 May-Jun       Impact factor: 1.372

9.  The relationship between polymorphonuclear granulocytes and cartilage destruction in rheumatoid arthritis.

Authors:  W Mohr; D Wessinghage
Journal:  Z Rheumatol       Date:  1978 Mar-Apr       Impact factor: 1.372

  9 in total
  11 in total

1.  A human model of platelet-leucocyte adhesive interactions during controlled ischaemia in patients with peripheral vascular disease.

Authors:  L Pasqualini; M Pirro; R Lombardini; G Ciuffetti; P Dragani; E Mannarino
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

2.  Poly L-histidine. A potent stimulator of superoxide generation in human blood leukocytes.

Authors:  I Ginsburg; R Borinski; M Sadovnic; Y Eilam; K Rainsford
Journal:  Inflammation       Date:  1987-09       Impact factor: 4.092

Review 3.  Variability in response to NSAIDs. Fact or fiction?

Authors:  R O Day; G G Graham; K M Williams; P M Brooks
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

4.  Non-steroidal Anti-inflammatory Drugs: Monitoring to help prevent serious adverse effects.

Authors:  B Cardario; A A McKinnon
Journal:  Can Fam Physician       Date:  1991-01       Impact factor: 3.275

5.  Alterations in neutrophil superoxide production following piroxicam therapy in patients with rheumatoid arthritis.

Authors:  D E Van Epps; S Greiwe; J Potter; J Goodwin
Journal:  Inflammation       Date:  1987-03       Impact factor: 4.092

6.  Superoxide production by polymorphonuclear leucocytes in rheumatoid arthritis and osteoarthritis: in vivo inhibition by the antirheumatic drug piroxicam due to interference with the activation of the NADPH-oxidase.

Authors:  P Biemond; A J Swaak; J M Penders; C M Beindorff; J F Koster
Journal:  Ann Rheum Dis       Date:  1986-03       Impact factor: 19.103

Review 7.  Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-10       Impact factor: 9.546

8.  Effects of cyclooxygenase inhibition on anastomotic healing following large bowel resection in a rabbit model--a randomized, blinded, placebo-controlled trial.

Authors:  Heiko Neuss; Wieland Raue; Verena Müller; Wilko Weichert; Wolfgang Schwenk; Julian W Mall
Journal:  Int J Colorectal Dis       Date:  2009-01-29       Impact factor: 2.571

Review 9.  The problems and pitfalls of NSAID therapy in the elderly (Part II).

Authors:  A G Johnson; R O Day
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

10.  Lipoteichoic acid-antilipoteichoic acid complexes induce superoxide generation by human neutrophils.

Authors:  I Ginsburg; S E Fligiel; P A Ward; J Varani
Journal:  Inflammation       Date:  1988-12       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.